Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 121,433 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
Interventions: Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography; Device · Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Erectile Dysfunction
Interventions: Udenafil, Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 36
States / cities: Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 32 more

Conditions: Urinary Tract Infections
Interventions: Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 1,606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 79
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 66 more

Conditions: Pseudofolliculitis Barbae
Interventions: shave gel, Brush; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 20 Years to 60 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Asthma
Interventions: BDA MDI, AS MDI; Drug
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 12 Years and older
Enrollment: 2,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more

Conditions: Obesity, Healthy Volunteers
Interventions: S309309, Itraconazole; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sleep, Relaxation, Stress, Daytime Sleepiness
Interventions: Sleep Supplement; Dietary Supplement
Lead sponsor: Athletic Greens International; Industry
Eligibility: 22 Years to 59 Years
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C, Chronic
Interventions: Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: La Jolla, California • Sacramento, California • Orlando, Florida + 14 more

Conditions: Cystic Fibrosis
Interventions: hyperpolarized Xenon gas; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 21 Years
Enrollment: 20 participants
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Interventions: Virtual Consult Intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Fever, Brain Hemorrhage
Interventions: Gaymar Rapr-Round (external cooling blanket); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vitamin D Deficiency, Metabolic Syndrome, Prediabetes
Interventions: Mushroom with 600 IU vitamin D2, Mushroom with 4000 IU Vitamin D2, 600 IU Vitamin D3 and untreated mushroom, 4000 IU Vitamin D3 and untreated mushroom, Placebo; Dietary Supplement · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 30 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Castrate-Resistant Prostate Cancer
Interventions: Atezolizumab, Radium-223 Dichloride; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Duarte, California • San Francisco, California • New Haven, Connecticut + 14 more

Conditions: Cirrhosis, Liver, Liver Diseases
Interventions: Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma, Recurrent Brain Neoplasm
Interventions: Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim; Other · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Myelodysplastic Syndromes
Interventions: Atezolizumab, Azacitidine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 15
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV
Interventions: Bemnifosbuvir, Ruzasvir; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: conventional surgery, brachytherapy, radiation therapy; Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 10
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COPD
Interventions: Arformoterol tartrate inhalation solution, Salmeterol MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 52
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 49 more

Conditions: Carpal Tunnel Syndrome, Median Nerve Injury
Interventions: Cooling, Heating, Exercising, Typing, Using a mouse, Cooking; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Columbus, Ohio

Conditions: Stress, Acculturation, Health
Interventions: Observational; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 44 Years
Enrollment: 390 participants
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Overweight, Obesity
Interventions: Active and Healthy Families; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 5 Years to 12 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburg, California • San Pablo, California

Conditions: Malignant Solid Tumour
Interventions: INNO-206; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Santa Monica, California

Search by objective public record fields.

Multimodal Ocular Imaging in Neurodegeneration

Treatment of Erectile Dysfunction I

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

Pre-Shave Gel and Brush in Pseudofolliculitis Barbae

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

Sleep and Morning Wellbeing Study

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI

Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

Temperature Control in Central Fever in the Neuro-ICU

Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Telehealth Intervention in Cirrhotics

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Sonographic Measurement of Intraneural Blood Flow in the Median Nerve

SER Hispano Longitudinal Study

Impact of Active and Healthy Families

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors